Furthermore, we highlight recent advances in identifying predictive biomarkers—such as genetic mutations (e.g., BAP1, MBD4), immune gene signatures, circulating tumor DNA, and protein-based blood markers—that may facilitate patient stratification and treatment selection. Here, MBD4 is linked to neoplasm.